Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

>JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study for the treatment of moderate to severe plaque psoriasis

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

>The sNDA for toripalimab in combination with disitamab vedotin as the treatment of HER2-expressing locally advanced or metastatic UC has been accepted by the NMPA.

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.